~~<i id='05B9602835'><strike id='05B9602835'><tt id='05B9602835'><pre id='05B9602835'></pre></tt></strike></i>~~

Home» focus» explore

explore

author：knowledge 2025-10-06 06:28:08 Page View：3

Venture capitalist Alexis Borisy Vanessa Leroy for STAT

EQRx is done, sold for its cash.

The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medicaid rebukes states for mistakenly disenrolling children
Next article： After affirmative action ruling, medical educators look to 'holistic review'

explore

Psychedelics group wrestles with new pharma identity

OliviaGoldhill/STATDENVER—Hecouldhavebeenarockstar,areligiousicon,thewayecstaticapplausefromthousand

Listen: Biogen's potential pivot, & Illumina's next chapter

Aretherestilltoomanybiotechcompanies?Howdoyouknowwhenyou’reinabubble?Andisthereawrongwaytopronounce“

Bright Health sells Medicare Advantage business to Molina

BrightHealthisofficiallyleavingthehealthinsurancemarket.ThecompanyhasagreedtosellitsMedicareAdvantag

Ebola vaccine can save some who are already sick, per new study

Anewstudyshowsthatinadditiontopreventinginfections,theEbolavaccinecansavesomepeoplewhoarealreadysick